Validea's guru fundamental report indicates that Thermo Fisher Scientific (TMO) is a large-cap growth stock with a 66% rating based on their P/B Growth Investor model, inspired by Partha Mohanram's strategy focusing on low book-to-market stocks with sustained growth characteristics; the model positively assesses TMO's book/market ratio, return on assets, and cash flow metrics, but flags the firm's advertising, capital expenditures, and R&D spending relative to assets.
Thermo Fisher Scientific Inc. (TMO), a large-cap growth stock within the Medical Equipment & Supplies industry, has received a 66% rating from Validea's P/B Growth Investor model, a strategy developed by Partha Mohanram focused on identifying low book-to-market stocks with sustained growth characteristics. This score, while indicating some positive attributes, falls short of the 80% level that Validea typically associates with significant model interest. TMO successfully meets the model's criteria for its book/market ratio, return on assets, cash flow from operations to assets, the consistency of cash flow relative to return on assets, return on assets variance, and sales variance. Conversely, the company fails the model's tests for advertising to assets, capital expenditures to assets, and research and development to assets, suggesting potential underinvestment in these areas relative to its asset base according to this specific growth-oriented framework. The overall sentiment for TMO is mildly positive, reflecting this mixed quantitative assessment.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
